Cancer Research

Axelar Receives Financing For A Phase I/II Clinical Trial On Cancer Patients With The New Anti-Cancer Drug AXL1717

STOCKHOLM, Sweden, June 12 /PRNewswire/-- Axelar AB today announced that the company has received financing from Östersjöstiftelsen (the Foundation for Baltic and East European Studies) and Karolinska Development AB to perform a Phase I/II clinical trial ...

Article - Anna Ohlden - Jun 12 2008 - 6:32am

Sleuthing The Evolutionary Trail Of Lou Gehrig's Disease

In a report in the current issue of the journal Cell, Dr. Hugo Bellen and colleagues at Baylor College of Medicine along with Dr. Michael Miller from the University of Alabama at Birmingham show how a single mutation in the human form of the VAMP-Associate ...

Article - News Staff - Jun 12 2008 - 12:20pm

Data Show That Abbott's HUMIRA(R) (adalimumab) Reduced The Signs And Symptoms Of Ankylosing Spondylitis Up To Three Years

PARIS, June 13 /PRNewswire/-- Abbott announced new data from the open-label extension of the ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS) phase III clinical trial, which showed HUMIRA(R) (adalimumab) reduced the signs and sympto ...

Article - Anna Ohlden - Jun 13 2008 - 1:16am

New Long-Term HUMIRA(R) (adalimumab) Data Show Up To Seven-Year Efficacy With Combination Treatment For Rheumatoid Arthritis

PARIS, June 13 /PRNewswire/-- Seven-year rheumatoid arthritis (RA) data from open-label extension studies show that treatment with Abbott's HUMIRA(R) (adalimumab) resulted in clinical remission among long-standing RA patients when used in combination ...

Article - Anna Ohlden - Jun 13 2008 - 1:16am

HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted In Cost Savings Fr

PARIS, June 13 /PRNewswire/--- Rheumatoid Arthritis is the Leading Cause of Work Disability in Europe ...

Article - Anna Ohlden - Jun 13 2008 - 1:16am

Treating Pain Effectively- New Study Results Confirm Improved Gastrointestinal Tolerability Of Tapentadol

PARIS and AACHEN, Germany, June 13 /PRNewswire/-- Results from two phase III clinical studies of tapentadol immediate release tablets (IR) suggest a significantly improved gastrointestinal tolerability(1) as well as safety(2) profile compared to oxycodone ...

Article - Anna Ohlden - Jun 13 2008 - 4:33am

New Roche Chlamydia Test Approved For Use In European Union

PLEASANTON, California, June 13 /PRNewswire/--- Test offers more reliable detection of Chlamydia trachomatis, the most commonly reported sexually transmitted disease in Europe. ...

Article - Anna Ohlden - Jun 13 2008 - 5:30am

VELCADE(R) (bortezomib) Data Highlights Superior Quantity And Quality Responses

BEERSE, Belgium, June 14 /PRNewswire/--- 30 Percent Complete Response Rate Compared to 4 Percent With Current Drug Treatment Standard of Care- Abstract Number: 0473 ...

Article - Anna Ohlden - Jun 14 2008 - 10:30am

Children From Three Primary Schools Meet Prince William At Charity Polo Match For WellChild

CHELTENHAM, England, June 14 /PRNewswire/--- With Photo Children from Bishop Stortfor College, Hornsby House School in South London and The Catholic School of St Gregory The Great in Cheltenham had the chance to show some of their artwork to Prince Willia ...

Article - Anna Ohlden - Jun 14 2008 - 4:30pm

Coffee Drinkers Have Slightly Lower Death Rate From Heart Disease

A new study published today in Annals of Internal Medicine has good news for coffee drinkers: Regular coffee drinking (up to 6 cups per day) is not associated with increased deaths in either men or women. In fact, both caffeinated and decaffeinated coffee ...

Article - News Staff - Jun 16 2008 - 7:41pm